Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.

Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Squamous Cell
Combined Modality Therapy
Drug Administration Schedule
Erythropoietin
Female
Fluorouracil
Head and Neck Neoplasms
Humans
Hydroxyurea
Male
Middle Aged
Paclitaxel
Recombinant Proteins
Survival Rate
Treatment Outcome

authors with profiles

Daniel J. Haraf
Kerstin M. Stenson
Bruce E. Brockstein
Louis Portugal
Ralph R. Weichselbaum
Everett E. Vokes